Medtronic PLC (NYSE: MDT) unveiled findings from the Enable Hernia Repair clinical study focusing on the Hugo robotic-assisted surgery system's efficacy in inguinal and ventral hernia repairs. The study, involving 193 patients utilizing the Medtronic Hugo RAS system, marks the first completed Investigational Device Exemption (IDE) clinical trial for robotic hernia surgery in the U.S. Results showcased a surgical success rate of 100%. MDT stock surged following the announcement. The Enable Hernia Repair study is a prospective, multi-center, single-arm pivotal trial with primary safety and effectiveness endpoints achieved. For more details, access the full story on Benzinga.com.